How is the world aligning when it comes to unique device identification (UDI)? Why is it important to understand where a medical device has been used, where it exists in the supply chain, and where it exists at any given point in time? 

[Related: Looking for more information on UDI? Click here to access a recording of our January webinar featuring author Mark Agostino.]

UDI webinar banner - January 2022 - download

The development of UDI has been a long time in the making, from the involvement of the Global Harmonization Task Force (GHTF) (now the International Medical Device Regulators Forum (IMDRF)) to ongoing adoption by many countries. Regulators and manufacturers recognize the benefits of UDI in dealing with product quality issues and managing supply chain activities.

The requirements for a UDI system are noted in U.S 21 CFR Part 830 and in Article 27 of 2017/745 EU Medical Device Regulation (EU MDR). In addition, MDCG 2021-19 Guidance note integration of the UDI within an organization`s quality management system provides detail on implementation requirements for an organization.

Throughout the presentation, the following questions were explored:

  • What standards and guidelines form the basis for UDI?
  • What are the benefits of UDI?
  • How should UDI be effectively incorporated into a company’s quality management system (QMS)?
  • What does harmonization of UDI mean?

During the virtual International Conference on Medical Device Standards and Regulation, Lena Cordie-Bancroft, BSI Sector Lead-Medical Devices, provided insights into the various aspects of UDI from her expertise in the area.

Basics of UDI

Cordie-Bancroft began the presentation with a brief explanation of UDI. She explained that UDI program includes “a set of rules and standards for assigning the UDI and for the various data elements associated with the UDI that are required for the control of the database and that data.”

She also clarified the differences between unique device identification and identifiers, both of which may be abbreviated UDI (Figure 1). 

Figure 1 UDI Definition
FIGURE 1 | Unique Device Identification versus Identifier

The UD-Identifier consists of an automated identification code (AIDC) and alphanumeric characters placed on a medical device label. A carrier contains UDI information. Figure 2 shows a specific symbol to indicate the UDI carrier on the label for a medical device. She also pointed out that the labeling standing, ISO 15223-1:2021, has been recently updated to include information on UDI carriers.

Figure 2 ISO 15223-1 UDI Carrier identifier
FIGURE 2 | ISO 15223-1 UDI Carrier identifier

The UDI carrier is comprised of two parts: UDI-DI and UDI-PI, which are the UDI device identifier and the UDI production identifier, respectively. UDI-DI is critical for the identification of the device and the device manufacturer. UDI-PI is crucial for traceability all the way to the patient/user level. These elements speak to the function of UDI and its design, identifying a device down to the patient/user level which directly impacts many functions within a company’s organization.

Cordie-Bancroft then outlined the benefits of UDI as shown in Figure 3, stating that “FDA, in starting to roll out their UDI guidance over ten years ago, indicated that UDI was meant to increase patient safety and help optimize patient care.”

Figure 3 UDI Benefits
FIGURE 3 | UDI Benefits

IMDRF adopted a similar position in the creation of its guidance documents. As the UDI discussion has continued over the years, manufacturers realize that the guidance and associated documents relate more to the supply chain. UDI benefits both patient safety/patient care and the supply chain. Such benefits include recall activities and reconciling devices sent to market. For example, healthcare personnel must enter critical information into a medical device’s UDI, such as each instance the device is used. This could potentially reduce human error in healthcare settings.

Implementing Expectations and Requirements for UDI Systems

In September 2012, IMDRF published the Unique Device Identification System for Medical Devices. This document, and the overall roadmap for the implementation of UDI systems, was built upon from the work started by the GHTF.

According to Cordie-Bancroft, this document “defines the pathway for regulatory bodies such as the European Union and Australia to implement a globally harmonized approach for UDI systems.” She emphasized that manufacturers and healthcare personnel should be very excited about this opportunity “to establish a context of alignment across the medical device landscape for UDI” as “understanding the tools and approaches that various regulatory bodies are utilizing helps promote predictability worldwide.”

IMDRF UDI Documents

Below are IMDRF documents Cordie-Bancroft referenced to help learn the requirements for implementing a UDI system. These documents are meant to address the various aspects of UDI that impact manufacturers.

Building a UDI Program – Manufacturer

Figure 4 illustrates the concepts behind the development of UDI. The approach outlined in the IMDRF guidance documents is closely aligned with FDA. This is, in part, due to the involvement by FDA during the discussions within the IMDRF. Although the idea was to harmonize throughout the world, differences exist among the various countries that preclude the universal adoption of UDI.  

Figure 4 Fundamental Concepts of UDI
FIGURE 4 | Fundamental Concepts of UDI

In principle, however, FDA and IMDRF are in alignment with respect to UDI. Therefore, addressing the key elements in Figure 5 will set an organization up for success in managing UDI at a global level. Following the IMDRF guidance documents noted above, which are aligned among international regulatory agencies, will lead to a sustainable global UDI program for an organization. The basic elements center on procedures and processes for the development of UDI, the application of UDI, and the submission of data to the appropriate UDI database.

Figure 5 Elements of a UDI Program
FIGURE 5 | Elements of UDI Program

Cordie-Bancroft also provided a list of relevant questions that a manufacturer must address when implementing UDI (Figure 6). The questions pertain to labeling, design, and regulatory submission challenges plus challenges that relate to the application of UDI during the design and development of a medical device as a company prepares for worldwide regulatory submissions.

Figure 6 Considerations for Implementation
FIGURE 6 | Considerations for Implementation

She emphasized that there are three important aspects toward building a sustainable UDI program:

  1. The data identifying the UDI
  2. The labels containing the information to be read
  3. The QMS governing the process (Figure 7)

The control of the information and its consistency between the data of the UDI and the labels will help during audits. The consistency of the data and following the established processes and procedures will also ensure that the UDI program upholds to regulatory scrutiny.

Figure 7 Sustainable UDI Program
FIGURE 7 | Sustainable UDI Program

In summary, there has been a great deal of effort to formulate a UDI system that can work effectively through an entire supply chain up to, and including, the end user, to identify a medical device. There are many key elements that manufacturers need to consider in developing a robust UDI system to work in their organization and to meet regulatory expectations.

[Editor’s Note: Part II provides further insights into UDI requirements.]

UDI webinar banner - January 2022 - download

Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Webinar: Comparing and Analyzing Russian, UK, and US Top Ten Pharma Inspection Findings FY 2019

Presented by Jerry Chapman on October 29, 2020

What you will learn:

  • A comparison of 483 observations in FY2019
  • Top 10 Russian Ministry of Health inspection findings
  • Top 10 FDA Warning Letter findings
  • Top MHRA inspection findings
Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Systems

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Champion of Change - 3Cs to Success

Webinar: Champion of Change - 3Cs to Success

Presented by Steve Greer on June 23, 2020

What you will learn:

  • The 3C Model to become a champion of change
  • How to identify game-changing habits and the steps to implement them
  • Ways to develop greater purpose-centered leadership
  • How to generate awareness along with actions to create changes in how you think about challenges and change putting you on a path to lead change successfully in your organization
  •  

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.